Company Profile
Clinuvel Pharmaceuticals Limited, a biopharmaceutical company focuses on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening disorders globally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).
The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. It is also developing NEURACTHEL (ACTH), an adrenocorticotropic hormone for targeting neurological, endocrinological, and degenerative disorders
Pharmaceutical formulations melanocortin technology for the treatment of a range of disorders Photocosmetic products for individuals and populations at risk of exposure to ultraviolet and high energy visible light, and in need of assistance in DNA repair and melanogenesis of the skin. Incorporated in 1999, the company is headquartered in Melbourne, Australia.